Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00027859
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : January 27, 2010
National Cancer Institute (NCI)
Southwest Oncology Group
Cancer and Leukemia Group B
Information provided by:
Eastern Cooperative Oncology Group

Brief Summary:

RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as ketoconazole may stop the production of androgens. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether hormone therapy is more effective than combination chemotherapy in treating prostate cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of hormone therapy with that of combination chemotherapy in treating patients who have prostate cancer that has been previously treated with androgen suppression.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: docetaxel Drug: estramustine phosphate sodium Drug: ketoconazole Drug: therapeutic hydrocortisone Phase 3

Detailed Description:


  • Compare time to objective progression in patients with prostate cancer and a rising prostate-specific antigen (PSA) after androgen suppression when treated with second-line hormonal therapy (ketoconazole and hydrocortisone) vs combination chemotherapy (docetaxel and estramustine).
  • Compare time to PSA progression and correlate this with time to objective progression in patients treated with these regimens.
  • Compare the quality of life in patients treated with these regimens.
  • Compare overall survival of patients treated with these regimens.
  • Compare the natural history of progression in patients treated with these regimens.
  • Identify prognostic indicators of clinical outcome by immunohistochemical evaluation of apoptopic biomarkers in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prior treatment with bisphosphonates (yes vs no). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral ketoconazole three times daily and oral hydrocortisone twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive oral estramustine three times daily on days 1-5 and docetaxel IV over 1 hour on day 2. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, on day 1 of week 9, at 6 months and 1 year, and then annually for up to 10 years or until beginning of first non-protocol therapy.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years.

PROJECTED ACCRUAL: A total of 590 patients (295 per treatment arm) will be accrued for this study within 4 years.

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Primary Purpose: Treatment
Official Title: A Phase III Randomized Trial for Evaluating Second Line Hormonal Therapy (Ketoconazole/Hydrocortisone) Versus Paclitaxel/Estramustine Combination Chemotherapy on Progression Free Survival in Asymptomatic Patients With a Rising PSA After Hormonal Therapy for Prostate Cancer
Study Start Date : May 2003
Actual Primary Completion Date : December 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Histologically confirmed adenocarcinoma of the prostate that was continuously treated with androgen suppression
  • Rising prostate-specific antigen (PSA), defined as PSA > 5 ng/mL, rising on 2 consecutive measurements at least 4 weeks apart
  • Gleason score 7 or higher and/or seminal vesicle involvement at diagnosis
  • Patients previously treated with antiandrogen or glucocorticoid therapy must meet the following criteria:

    • Must show a continued rise in PSA after stopping antiandrogen (flutamide, bicalutamide, or nilutamide) or glucocorticoid (dexamethasone or prednisone)

      • At least 4 weeks continued rise in PSA after flutamide or nilutamide (6 weeks for bicalutamide)
  • Testosterone less than 50 ng/dL

    • Patients who have not undergone surgical castration must continue primary androgen suppression to maintain castrate levels of testosterone
  • No progressive or measurable local or metastatic disease (including bone metastases)



  • 18 and over

Performance status:

  • ECOG 0-1

Life expectancy:

  • Not specified


  • Granulocyte count at least 2,000/mm^3
  • Platelet count at least 100,000/mm^3


  • SGOT no greater than 2 times upper limit of normal
  • Bilirubin no greater than 1.5 mg/dL


  • Creatinine no greater than 1.7 mg/dL


  • No American Heart Association class III or IV heart disease
  • No uncontrolled congestive heart failure
  • No life-threatening cardiac arrhythmias


  • Fertile patients must use effective contraception
  • No other prior malignancy unless curatively treated and disease-free for appropriate time period for specific cancer
  • No preexisting peripheral neuropathy greater than grade 1
  • No known hypersensitivity to polysorbate 80


Biologic therapy:

  • Not specified


  • At least 5 years since prior systemic chemotherapy

Endocrine therapy:

  • See Disease Characteristics
  • At least 4 weeks since prior hydrocortisone
  • No prior ketoconazole


  • At least 28 days since prior radiotherapy to primary site
  • No prior palliative radiotherapy
  • No concurrent radiotherapy


  • See Disease Characteristics


  • Recovered form prior therapy
  • At least 7 days since prior parenteral antibiotics for active infection
  • No concurrent digitalis
  • No concurrent H_2 blockers or proton pump inhibitors (arm I only)
  • Concurrent bisphosphonates allowed provided they were initiated prior to study therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00027859

  Show 98 Study Locations
Sponsors and Collaborators
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Southwest Oncology Group
Cancer and Leukemia Group B
Study Chair: Michael A. Carducci, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study Chair: Nirmala Bhoopalam, MD Veterans Affairs Medical Center - Hines
Study Chair: Gregory P. Swanson, MD Deaconess Medical Center, Spokane, Washington
Study Chair: William Dahut, MD National Cancer Institute (NCI)

Publications of Results:
Responsible Party: Group Chair, Eastern Cooperative Oncology Group Identifier: NCT00027859     History of Changes
Other Study ID Numbers: CDR0000069088
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: January 27, 2010
Last Verified: January 2010

Keywords provided by Eastern Cooperative Oncology Group:
adenocarcinoma of the prostate
stage III prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Hydrocortisone 17-butyrate 21-propionate
Genital Diseases, Male
Prostatic Diseases
Hydrocortisone acetate
Cortisol succinate
Anti-Inflammatory Agents
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors
Antineoplastic Agents, Alkylating
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal